ImmunoGen, Inc. Initiates Phase I Trial of IMGN853 in Ovarian Cancer and Other Solid Tumors ...
09:15 EDT 11 Jul 2012 | LaMerie
– Folate receptor 1 (FOLR1)-targeting compound is second novel ImmunoGen product candidate to enter clinic this year –
Original Article: ImmunoGen, Inc. Initiates Phase I Trial of IMGN853 in Ovarian Cancer and Other Solid Tumors ...
More From BioPortfolio on "ImmunoGen, Inc. Initiates Phase I Trial of IMGN853 in Ovarian Cancer and Other Solid Tumors ..."
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
